Page last updated: 2024-10-30

mazindol and Weight Loss

mazindol has been researched along with Weight Loss in 9 studies

Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.

Weight Loss: Decrease in existing BODY WEIGHT.

Research Excerpts

ExcerptRelevanceReference
" We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D."9.51Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. ( Arguelles-Tello, FA; Barranco-Garduño, LM; Huerta-Cruz, JC; Kammar-García, A; Reyes-García, JG; Rocha-González, HI; Trejo-Jasso, CA, 2022)
"The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients."8.95Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. ( Correr, CJ; Fernandez-Llimos, F; Lucchetta, RC; Otuki, MF; Pontarolo, R; Radominski, RB; Riveros, BS, 2017)
" We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D."5.51Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. ( Arguelles-Tello, FA; Barranco-Garduño, LM; Huerta-Cruz, JC; Kammar-García, A; Reyes-García, JG; Rocha-González, HI; Trejo-Jasso, CA, 2022)
"Mazindol was given orally, 1."5.29Effects of mazindol in two patients with Prader-Willi syndrome. ( Itoh, M; Koeda, T; Ohno, K; Takeshita, K, 1995)
"To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss."5.19A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. ( Boguszewski, CL; Cunha, DR; do Desterro de Figueiredo, M; dos Santos, CM; Radominski, R; Suplicy, H, 2014)
" The two phenylpropanolamine studies gave the same weight losses, but the dropouts were 37% at 8 weeks for free care vs."5.09Methods to maximize retention in weight loss studies. ( Bray, GA; Greenway, FL; Marlin, RL, 1999)
"The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients."4.95Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. ( Correr, CJ; Fernandez-Llimos, F; Lucchetta, RC; Otuki, MF; Pontarolo, R; Radominski, RB; Riveros, BS, 2017)
"To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk."3.70Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999)
"Mazindol was given orally, 1."1.29Effects of mazindol in two patients with Prader-Willi syndrome. ( Itoh, M; Koeda, T; Ohno, K; Takeshita, K, 1995)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19901 (11.11)18.7374
1990's4 (44.44)18.2507
2000's1 (11.11)29.6817
2010's2 (22.22)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Arguelles-Tello, FA1
Kammar-García, A1
Trejo-Jasso, CA1
Huerta-Cruz, JC1
Barranco-Garduño, LM1
Rocha-González, HI1
Reyes-García, JG1
Lucchetta, RC1
Riveros, BS1
Pontarolo, R1
Radominski, RB1
Otuki, MF1
Fernandez-Llimos, F1
Correr, CJ1
Suplicy, H1
Boguszewski, CL1
dos Santos, CM1
do Desterro de Figueiredo, M1
Cunha, DR1
Radominski, R1
Mancini, MC1
Halpern, A1
Itoh, M1
Koeda, T1
Ohno, K1
Takeshita, K1
Ryan, DH2
Bray, GA3
Helmcke, F1
Sander, G1
Volaufova, J1
Greenway, F1
Subramaniam, P1
Glancy, DL1
Greenway, FL2
Rood, JC1
Tucker, EW1
Smith, SR1
Marlin, RL1
Murphy, JE1
Donald, JF1
Molla, AL1
Crowder, D1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Sulphate-bicarbonate-calcium Water Consumption on the Body Weight and Gut Microbiota Composition in Overweight and Obese Patients Under Low-calorie Diet[NCT02154230]0 participants (Actual)Interventional2013-11-30Withdrawn (stopped due to failure to enroll)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for mazindol and Weight Loss

ArticleYear
Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.
    Clinics (Sao Paulo, Brazil), 2017, Volume: 72, Issue:5

    Topics: Appetite Depressants; Diethylpropion; Humans; Mazindol; Obesity; Overweight; Publication Bias; Repro

2017
Pharmacological treatment of obesity.
    Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:2

    Topics: Amphetamines; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Ene

2006

Trials

4 trials available for mazindol and Weight Loss

ArticleYear
Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects.
    International journal of clinical pharmacology and therapeutics, 2022, Volume: 60, Issue:8

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglyc

2022
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
    International journal of obesity (2005), 2014, Volume: 38, Issue:8

    Topics: Adult; Amphetamines; Anti-Obesity Agents; Body Mass Index; Brazil; Cyclobutanes; Diet, Reducing; Die

2014
Methods to maximize retention in weight loss studies.
    Obesity research, 1999, Volume: 7, Issue:6

    Topics: Appetite Depressants; Double-Blind Method; Humans; Mazindol; Patient Dropouts; Patient Selection; Ph

1999
A comparison of mazindol (Teronac) with diethylpropion in the treatment of exogenous obesity.
    The Journal of international medical research, 1975, Volume: 3, Issue:3

    Topics: Adult; Diethylpropion; Female; Humans; Male; Mazindol; Middle Aged; Obesity; Weight Loss

1975

Other Studies

3 other studies available for mazindol and Weight Loss

ArticleYear
Effects of mazindol in two patients with Prader-Willi syndrome.
    Pediatric neurology, 1995, Volume: 13, Issue:4

    Topics: Adolescent; Appetite Depressants; Central Nervous System Stimulants; Child; Humans; Male; Mazindol;

1995
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
    Obesity research, 1999, Volume: 7, Issue:4

    Topics: Aortic Valve Insufficiency; Appetite Depressants; Body Mass Index; Counseling; Dexfenfluramine; Drug

1999
Pharmaceutical cost savings of treating obesity with weight loss medications.
    Obesity research, 1999, Volume: 7, Issue:6

    Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug

1999